drugset / Trial / NCT01109316

Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

NCT01109316

Phase 3 Completed 132 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelTreatment

Summary

This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose of this study is to provide information on the use of insulin lispro in insulin pumps (Continuous Subcutaneous Insulin Infusion \[CSII\]) compared to insulin aspart over 6 days of pump reservoir in-use. The study will also compare the in-use characteristics of insulin lispro infused at 6 days with insulin lispro infused at 2 days.

Timeline

Start
2010-04
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Lispro Protein / enzyme biologic Subcutaneous
Comparator insulin aspart Protein / enzyme biologic Subcutaneous